Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
CONCLUSIONS: The addition of abiraterone acetate to androgen deprivation therapy improves overall survival but probably not quality of life. ItÃÂ probably also extends disease-specific survival, and delays disease progression compared to androgen deprivation therapy alone. However, the risk of grades III to V adverse events is increased, and probably, so is the risk of discontinuing treatment due to adverse events.
PMID: 33314020 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Sathianathen NJ, Oestreich MC, Brown SJ, Gupta S, Konety BR, Dahm P, Kunath F Tags: Cochrane Database Syst Rev Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Cancer Therapy | Conferences | Databases & Libraries | General Medicine | Hormonal Therapy | Hormones | Prednisolone | Prednisone | Prostate Cancer | Statistics | Study